Rasagiline Rescue in Alzheimer's Disease Clinical Trial

The study consists of two phases: a 24 week double blind placebo controlled treatment period
and a 4 week follow up period. Patients will be randomized in a 1: 1 ratio at baseline to
receive either Rasagiline or matching placebo

The study drug will be given as 0.5 mg dose once daily for the 4 weeks, then increases to 1
mg daily for the next 20 weeks. A total of 50 subjects will be enrolled: 25 will receive
Rasagiline and 25 will receive matching placebo for the 24-week treatment period.

Primary objective is to determine if exposure to 1 mg of Rasagiline daily is associated with
improved regional brain metabolism in the treatment group compared to the placebo group in
Alzheimer's Disease patients

Inclusion Criteria:

- Males or females 50 to 90 of age inclusive.

- Diagnosis of probable AD (NINCDS-ADRDA criteria)

- Positive fluoro-deoxyglucose PET ([18F]-FDG PET) scan compatible with AD as determined
by the ADM Diagnostics LLC (ADMdx) Criteria at screening

- Mini Mental Status Exam = 12 - 22 (inclusive)

- Must have a study partner who is able and willing to comply with all required study
procedures.

- Have at least eight years of education and should have previously (in pre-AD
condition) been capable of reading, writing, and communicating effectively with others
in English.

- If receiving therapy with a cholinesterase inhibitor and/or memantine, the dose of
these agents has been stable for at least 3 months prior to screening

Exclusion Criteria:

- Any non-AD neurological disease

- MRI findings indication of a non-AD diagnosis

- Screening laboratory studies that are 1.5 times above or below the highest and lowest
range of normal for each test respectively

- History of melanoma; history of malignancy within the past five years with the
exception of basal cell or squamous cell cancer, in-situ cervical cancer, or localized
prostate cancer